Hackensack University Medical Center Hematology and Medical Oncology

Fellowship · Hackensack, NJ

Sponsored by Hackensack Meridian Health · Director Christina Cho

Works by its people: 1,642
Authors: 40
First-author works: 282
Citations: 121,460

20112026

Topics

Multiple Myeloma Research and Treatments 348
Lymphoma Diagnosis and Treatment 203
CAR-T cell therapy research 88
Hematopoietic Stem Cell Transplantation 88
Chronic Lymphocytic Leukemia Research 65
Acute Myeloid Leukemia Research 46
Cancer Immunotherapy and Biomarkers 24
Cancer-related cognitive impairment studies 21
Chronic Myeloid Leukemia Treatments 17
Amyloidosis: Diagnosis, Treatment, Outcomes 16
Cutaneous lymphoproliferative disorders research 15
Cancer Cells and Metastasis 13

Most cited

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
The New England journal of medicine · 2021 · 2,130 citations · David Siegel
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
The New England journal of medicine · 2022 · 1,350 citations · Lori Leslie
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet (London, England) · 2024 · 686 citations · Andrew Pecora
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 506 citations · Tatyana Feldman
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
The Lancet. Oncology · 2022 · 573 citations · Lori Leslie
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood · 2023 · 409 citations · Andre Goy
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
The New England journal of medicine · 2023 · 409 citations · Lori Leslie
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 392 citations · Andrew Pecora

Topics

Multiple Myeloma Research and Treatments 348

Lymphoma Diagnosis and Treatment 203

CAR-T cell therapy research 88

Hematopoietic Stem Cell Transplantation 88

Chronic Lymphocytic Leukemia Research 65

Acute Myeloid Leukemia Research 46

Cancer Immunotherapy and Biomarkers 24

Cancer-related cognitive impairment studies 21

Chronic Myeloid Leukemia Treatments 17

Amyloidosis: Diagnosis, Treatment, Outcomes 16

Cutaneous lymphoproliferative disorders research 15

Cancer Cells and Metastasis 13

Most cited

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

The New England journal of medicine · 2021 · 2,130 citations · David Siegel

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

The New England journal of medicine · 2022 · 1,350 citations · Lori Leslie

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

Lancet (London, England) · 2024 · 686 citations · Andrew Pecora

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 506 citations · Tatyana Feldman

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

The Lancet. Oncology · 2022 · 573 citations · Lori Leslie

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Blood · 2023 · 409 citations · Andre Goy

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

The New England journal of medicine · 2023 · 409 citations · Lori Leslie

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 392 citations · Andrew Pecora